-
The RSA Group appoints Alex Bennett as CEO
London, UK, 12th September 2016 – The RSA Group, the world’s largest Talent Consultancy in Life Sciences, has announced the appointment of a new CEO, Alex Bennett. Alex comes to RSA with an international track record in senior level life sciences executive search, specialising in Medical Devices and Diagnostics. His most recent global leadership roles have been…
-
Cambridge Research Biochemicals® Launches New Discovery Peptides® Catalogue to the Life Science Community
Cambridge Research Biochemicals announces the release of its new Discovery Peptides® catalogue. Billingham, UK, 16th August 2016 / Sciad Newswire / Cambridge Research Biochemicals® (CRB), a British company specialising in custom peptides and bespoke antibodies for the Pharmaceutical industry and for medical research, today announced the release of its new Discovery Peptides® catalogue. Having delighted customers with the highest quality…
-
SynbiCITE and Rainbow Seed Fund Announce New £200k Competition for Engineering Biology
SynbiCITE and Midven announce the launch of Bio-Start, an annual competition to support early stage companies in the field of synthetic biology.
-
Finalists announced for OBN Awards 2016
Abingdon, UK, 3rd August 2016 / Sciad Newswire / OBN Ltd, the membership organisation supporting the UK’s innovative life sciences companies, today announces the finalists of its 8th Annual Awards covering Biotech, Medtech, Synthetic Biology and Digital Health. The OBN Awards remain proudly independent, celebrating innovation and achievement across the UK life sciences industry and recognising achievements from emerging to late…
-
SynBioBeta Aims to Fuel Your Passion for Engineering Biology at their 5th Annual San Francisco Conference
San Francisco, CA, USA, 28th July 2016 / Sciad Newswire / SynBioBeta announced today they will again be bringing together the synthetic biology community for the 5th Annual SynBioBeta SF 2015 Conference, which will be held at South San Francisco Conference Center, in California on October 4, 2016 – October 6, 2016. The aim of SynBioBeta SF 2016 is to “Fuel Your…
-
Prokarium Receives £2M In Government Contracts to Develop New Vaccines Against Emerging Diseases and Bioterrorist Threats
Prokarium announces funding from UK & Mexican Governments to develop vaccines against Zika, bacterial diarrhoea and Plague.
-
Biotechnology Veteran Joins Riffyn as Vice President of Product Development and Application Support
Oakland, CA, USA, 19th July 2016 / Sciad Newswire / Riffyn, a developer of cloud-based software for research and development, today announced that Dr. Tom Treynor has joined the company as Vice President of Product Development and Application Support. “Tom is one of the most talented and deeply experienced R&D process and quality engineers in the life science…
-
Cypralis Limited announces agreement with SCYNEXIS Inc. to acquire a large portfolio of cyclophilin inhibitor assets
Cypralis, a life sciences company focussed on the discovery of novel therapeutics based on modulation of peptidyl-prolyl isomerases (PPIases) has acquired a portfolio of cyclophilin inhibitor assets from SCYNEXIS Inc, a NASDAQ-listed company headquartered in New Jersey, USA.
-
Pearson Medical Technologies and XchangeLabs to Exhibit at RBC Cardinal 2016
Alexandria, LA, USA, 11th July 2016 / Sciad Newswire / Pearson Medical Technologies (Pearson), a leader in pharmacy automation solutions, will showcase at RBC Cardinal 2016 in Chicago, IL from July 20-23 with XchangeLabs. Pearson and XchangeLabs will be exhibiting in booth #2416, where retail and other pharmacies can learn more about the IP128APS Automated Multi-Dose Packaging System as well as …
-
Siemens Investment Accelerates Launch of Riffyn’s Ground-breaking R&D Design Software
Oakland CA, USA, 6th July 2016 / Sciad Newswire / Riffyn, Inc. announces an investment by Siemens Venture Capital to accelerate the launch of its cloud-based research process design software. The investment brings Riffyn’s funding to $4.6M including lead investments from Bioeconomy Capital and O’Reilly Alphatech Ventures (OATV). Riffyn’s product delivers a step-change in the pace and quality of research…